The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated With Cetuximab Combined With FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer

Disease Markers - Egypt
doi 10.1155/2019/6812045
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

FOLFIRI® and Bevacizumab in First-Line Treatment for Colorectal Cancer Patients: Safety, Efficacy and Genetic Polymorphisms

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2014English

Evaluation of Serum CEA and CA19-9 Levels as Prognostic Factors in Patients With Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2000English

Evaluation of Serum Levels of CEA and CA19-9 as Parameters of Following Up for Patients With Gastric Cancer.

Japanese Journal of Gastroenterological Surgery
SurgeryGastroenterology
1999English

Elevated CEA and CA19-9 Serum Levels Independently Predict Advanced Pancreatic Cancer at Diagnosis

Biomarkers
MutagenesisClinical BiochemistryBiochemistryHealthMedicineToxicology
2020English

PTEN Status in Advanced Colorectal Cancer Treated With Cetuximab

British Journal of Cancer
Cancer ResearchOncology
2009English

A Multi-Center Phase II Study and Biomarker Analysis of Combined Cetuximab and Modified FOLFIRI as Second-Line Treatment in Patients With Metastatic Gastric Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Serum CA19-9 as a Marker of Circulating Tumor Cells in First Reflux Blood of Colorectal Cancer Patients

Oncotarget
Oncology
2017English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Role of RAS Mutation Status as a Prognostic Factor for Patients With Advanced Colorectal Cancer Treated With First-Line Chemotherapy Based on Fluoropyrimidines and Oxaliplatin, With or Without Bevavizumab: A Retrospective Analysis

Molecular and Clinical Oncology
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy